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OBJECTIVE: To conduct a cost-beneﬁt analysis (CB) for the
Implantable Cardioverter Deﬁbrillators (ICDs) in the primary
prevention of Sudden Cardiac Death (SCD) compared to amio-
darone. METHODS: A discrete event simulation model was built
to determine the cost-beneﬁt ratio associated with ICDs from a
societal perspective in Canada using the “value of life” approach
as a measure of “beneﬁt”. The clinical inputs were derived from
the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
and the Amiodarone Trial Analysis (ATMA) studies. The related
costs were derived from the Ontario Health Insuranace Plans’
(OHIP) schedule of beneﬁts and fees, Ontario Drug Beneﬁt for-
mulary (ODB) and published data. The value of life in Canada
(CND$5.8Mil.), as determined by Health Canada, was used in
the model. One hundred replicaitons of 1000 identical twin pairs
over 7 years, aligned with the average life of an ICD, were run.
The costs (year 2006) and outcomes ere discounted at 3%.
Sensitivity Analysis (SAs) were performed for key input param-
eters. RESULTS: The absolute all-cause mortality was reduced by
eight percent with ICD over seven years compared to amio-
darone. The average costs associated with ICD and amiodarone
treatments were estimated as CND$32,000 and CND$6400 per
patient, respectively. The predicted cost-beneﬁt ratio (CBR) was
0.04. This ﬁgure suggests that for every $1 spent for ICD in the
primary prevention of SCD the society will gain $25 in “value”
by human lives saved. SAs showed that results were robust (CBR:
0.035–0.044). CONCLUSION: IDs reduce the risk of SCD due
to arrhythmia compared to amiodarone. The estimated CBR
suggests that ICDs are worthwhile investment from a societal
perspective in Canada. The initial investment for ICD in primary
prevention of SCD in Canada is comparable and in many cases
lower when compared to other societal programs for saving lives.
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OBJECTIVE: To evaluate the inﬂuence of research abstracts in
guiding evidence based decisions of the Ontario Cancer Drug
Approval Committee. METHODS: The Ontario Cancer Drug
Approval Committee is a joint initiative between the Ontario
Ministry of Health and Cancer Care Ontario that provides a
clinical and economic evaluation process for new cancer-related
drugs for formulary listing consideration. The minutes of the
monthly committee meetings between 2005 and 2007 were
reviewed. One submission per drug indication was included.
Elements from the decisions were entered into a database which
included the level of evidence supporting each decision, the loca-
tion from which the evidence originated, and the year the litera-
ture was produced. An abstract was deﬁned as anything in the
evidentiary base that was unpublished or was clearly deﬁned as
an abstract in the meeting minutes. RESULTS: There were
62 recommendations reviewed over the 27 months. Ten recom-
mendations were deferred and 8 recommendations were re-
submissions, thus 44 recommendations underwent analysis. The
subcommittee decisions were based on literature of varying levels
of evidence. There were 24 recommendations based on abstracts,
of which 14 (58%) were approved and 10 (42%) were rejected.
Eleven recommendations were based exclusively on abstracts, 7
(64%) of which were in favor of the new chemotherapy indica-
tion. Among the 20 recommendations not based on an abstract,
10 (50%) were approved and 10 (50%) were rejected. As a
comparison, published Randomized Control Trials were part of
the evidentiary base in 27 committee recommendations (61%).
Of these, 16 (59%) were in approval of a new chemotherapy
indication while 11 (41%) were opposed. CONCLUSION:
Research abstracts are commonly involved in evidence based
decision making for cancer drug funding. The rates of approving
cancer drugs for funding by the Ontario Cancer Drug Approval
Committee were similar among recommendations based on
abstracts and other levels of evidence.
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OBJECTIVE: The costs and beneﬁts of hepatitis C (HCV) screen-
ing among immigrants need to be assessed since about 20% of
HCV cases in Canada are immigrants. METHODS: A decision
analytic model was developed to assess HCV screening among
immigrants. The prevalence of hepatitis C and distributions of
viral genotypes among immigrants were projected by the studies
related to HCV epidemiology in their home countries. Meta-
analyses of randomized trials were conducted to estimate the
effectiveness of current anti-viral therapy (pegylated interferon
plus ribavirin) in terms of genotype and disease stage. Survival
regression model and logistic regression model were applied to
project the transition probabilities for the disease progression by
identifying cohort studies on the natural history of chronic HCV.
The awareness of the disease, and the HCV incidence among
immigrants were estimated using PHAC’s surveillance data. The
costs associated with HCV screening test, anti-viral therapy,
and health care were estimated through published literatures.
Cost-effectiveness analysis for immigrants was further stratiﬁed
by world regions. RESULTS: HCV screening was associated with
an increase of life years (0.0013 years) and cost ($40.6) when
compared to no screening for all immigrants ($30,552 per addi-
tional life year). HCV screening for immigrants born in South
Asia was associated with longer life years (0.0108 years) and less
cost (-$50.6). HCV screening strategy for immigrants born in
Africa cost $8635 to gain one additional life year. No obvious
advantages of HCV screening were observed for immigrants
from other areas. CONCLUSION: The preliminary ﬁndings
suggest that it may be cost-effective to screen immigrants from
South Asia and Africa. However, further studies are needed to
conﬁrm our ﬁndings.
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OBJECTIVE: Recent analyses from randomized clinical trials
(RCTs) indicate that, compared to generic simvastatin, atorvas-
Abstracts A3
